Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Conditions

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)

Interventions

• DRUG: Venetoclax monotherapy
• DRUG: Venetoclax with anti CD20 monoclonal antibody

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

• [object Object]